Tvardi Therapeutics is trading at $1.03, up 6.19%, amid broader biotech-sector strength. - The biotech sector is up 2.10%, providing same-direction context. - No clear company-specific catalyst has been identified. Management is scheduled to present at Chardan’s healthcare conference at 1:30 p.m. ET; the event is not established as the cause of the move.